Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study

BACKGROUND: Although treatment with imatinib in advanced gastrointestinal stromal tumor (GIST) patients has led to significant clinical benefits, the disease will eventually progress due to imatinib resistance. Treatment options after failure of first-line imatinib include imatinib dose escalation o...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Hsu, Jun-Te, Le, Puo-Hsien, Kuo, Chang-Fu, Chiou, Meng-Jiun, Kuo, Chia-Jung, Chen, Tsung-Hsing, Lin, Chun-Jung, Chen, Jen-Shi, Yu, Huang-Pin, Yeh, Chun-Nan, Jan, Yi-Yin, Yeh, Ta-Sen
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
Clinical Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642623/
https://ncbi.nlm.nih.gov/pubmed/29050348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16795
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים